November 7, 2013, Vancouver, Canada—iCo Therapeutics Inc. (TSX-V: ICO), today announced that Management will be presenting at the 5th Annual Ophthalmology Innovation Summit (OIS). A corporate presentation, highlighting the Company’s Phase 2 iDEAL Study for diabetic macular edema (DME), will take place at 10:54 am EST, Thursday November 14th, 2013 at the Sheraton New Orleans.
“We’re very happy to once again be invited to this prestigious event,” said Andrew Rae, President & CEO of iCo. “Our phase 2 study in patients with diabetic macular edema is ongoing with a recent endorsement of the Data and Safety Monitoring Committee. We are now preparing to report on our primary end point data in early 2014. This conference highlights a number of private and public companies, including some firms who have conducted high profile initial public offerings, and is a great platform to be in front of the who’s who in the ophthalmology space at a very critical time for the company”.
The OIS is a premier ophthalmology conference that seeks to unite leaders in the development of ophthalmic products, drugs, and devices. For more information please refer to: http://www.ophthalmologysummit.com/.
About iCo Therapeutics
iCo Therapeutics in-licenses and redefines existing drug candidates or generics by employing reformulation and delivery technologies for new or expanded use indications. The company has exclusive worldwide rights to two drug candidates – iCo-007 for Diabetic Macular Edema (DME) and iCo-008 for other sight-threatening diseases. iCo-007 is in Phase 2 clinical studies for DME. With Phase 2 clinical history, iCo-008 is targeted for the treatment of keratoconjunctivitis and wet age-related macular degeneration. In addition, iCo holds worldwide rights to an oral drug delivery platform. The first platform candidate is the Oral Amp B Delivery system, utilizing a known anti-fungal drug to treat life-threatening infectious diseases. iCo trades on the TSX Venture Exchange under the symbol “ICO”. For more information, visit the Company website at: icotherapeutics.cdmail.biz.
No regulatory authority has approved or disapproved the content of this release. The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
Forward Looking Statements
Certain statements included in this press release may be considered forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will,” and similar references to future periods. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on iCo’s current beliefs as well as assumptions made by and information currently available to iCo and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which are based only on information currently available to iCo and speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by iCo in its public securities filings and on its website, actual events may differ materially from current expectations. iCo disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
| iCo Therapeutics
604-602-9414 x 224